Zymeworks Competitors and Similar CompaniesClear all

NovoCure's competitors and similar companies include Coherus BioSciences, Gossamer Bio and Foghorn Therapeutics.
NovoCure
NovoCure
NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors.
Coherus BioSciences
Coherus BioSciences
Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments.
Gossamer Bio
Gossamer Bio
Gossamer Bio is a company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations.
Foghorn Therapeutics
Foghorn Therapeutics
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
Founding Date
Founding Date
2000
Founding Date
2010
Founding Date
2015
Founding Date
2016
Type
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Saint Helier, JE HQ
München, DE
Haifa, IL
Tokyo, JP
Root, CH
Malvern, US
New York, US
see more
Locations
Redwood City, US HQ
Camarillo, US
Locations
San Diego, US HQ
Dublin 2, IE
Locations
Cambridge, US HQ
Cambridge, US
Employees
Employees
1,453
Employees
30615% decrease
Employees
11820% increase
Employees
16135% increase
Valuation ($)
Valuation ($)
1.8 b
Valuation ($)
85.6 m
Valuation ($)
208 m
Valuation ($)
452 m

Financial

Revenue (est.)
Revenue (est.)
$509.3m (FY, 2023)
Revenue (est.)
$257.2m (FY, 2023)
Revenue (est.)
N/A
Revenue (est.)
$34.2m (FY, 2023)
Cost of goods
Cost of goods
$128.3m (FY, 2023)
Cost of goods
$159m (FY, 2023)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$381.1m (FY, 2023)
Gross profit
$98.3m (FY, 2023)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($207m) (FY, 2023)
Net income
($237.9m) (FY, 2023)
Net income
($179.8m) (FY, 2023)
Net income
($98.4m) (FY, 2023)

Operating

Phase II Trials Products
Phase II Trials Products
6 (FY, 2021)
Phase II Trials Products
1 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
3 (FY, 2021)
Phase III Trials Products
1 (FY, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Trials Products Approved
Trials Products Approved
3 (FY, 2021)
Trials Products Approved
1 (FY, 2020)
Trials Products Approved
N/A
Trials Products Approved
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 174.5m
Total funding raised
$ 480m
Total funding raised
$ 50m
For sources of this data, please see the company profile

View Company Profiles

Coherus BioSciences
HQ
Redwood City, US
Employees
306↓ 15% decrease

Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments.

View company
Gossamer Bio
HQ
San Diego, US
Employees
118↑ 20% increase

Gossamer Bio is a company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations.

View company
Foghorn Therapeutics
HQ
Cambridge, US
Employees
161↑ 35% increase

Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.

View company